# A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers

> **NCT03762031** · PHASE1 · COMPLETED · sponsor: **Galera Therapeutics, Inc.** · enrollment: 70 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GC4711 30mg
- **DRUG:** GC4711 60mg
- **DRUG:** GC4711 90mg
- **DRUG:** GC4711 120mg
- **DRUG:** Placebo
- **DRUG:** GC4711 75mg
- **DRUG:** GC4711 105mg

## Key facts

- **NCT ID:** NCT03762031
- **Lead sponsor:** Galera Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-19
- **Primary completion:** 2020-03-04
- **Final completion:** 2020-03-04
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2020-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03762031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03762031, "A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03762031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*